RxDoctor Payments Data

Patrick Allan, MD

Pulmonary Disease · Dayton, OHNPI 1609954940

Payments from drug & device makers

$15,194in general payments, 2019–2025

Across 486 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Pulmonx Corporation$2K
  • GSK$2K
  • AstraZeneca$991
  • Boehringer Ingelheim$402
  • Genentech USA, Inc.$365
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$2,42316%
  • Food & beverage$7,13047%
  • Education$5,64137%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,194 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$325,587
Medicare patients
1,124
Services billed
3,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate118$1,481,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,162$1,169,219
Prolastin CAlpha-1-Proteinase Inhibitor81$958,571
Dupixent PenDupilumab104$390,185
Breztri AerosphereBudesonide/Glycopyr/Formoterol256$256,541
Pirfenidone115$224,080
Spiriva RespimatTiotropium Bromide168$145,944
TezspireTezepelumab-Ekko28$118,599
Fasenra PenBenralizumab14$84,426
Breo ElliptaFluticasone/Vilanterol129$78,926
Stiolto RespimatTiotropium Br/Olodaterol Hcl78$61,084
NucalaMepolizumab13$45,334
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr77$37,885
SymbicortBudesonide/Formoterol Fumarate67$23,439
Albuterol Sulfate HfaAlbuterol Sulfate702$20,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$402$1,688,819364 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta$1,661$1,331,3651,381 claims
Grifols USA, LLCProlastin C$361$958,57181 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$991$398,580351 claims
PfizerEliquis$71$16,15522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →